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Abstract: Inflammation is in part defined by the transient upregulation of cell adhesion molecules on 
the surface of endothelial cells (ECs) in response to cytokines. We hypothesized that liposomes with a 
complementary surface presentation of antibodies to the pattern of molecules on the EC surface may 
enhance targeting. We quantified the expression of vascular cell adhesion molecule-1 (VCAM1) and 
endothelial leukocyte cell adhesion molecule-1 (E-selectin) on ECs upon exposure to either tumor 
necrosis factor-α (TNF-α) or interleukin-1α (IL-1α) as a function of time. Liposomes, composed of 95 
mol% dioleoyl phosphatidylcholine (DOPC) and 5 mol% dodecanyl phosphatidylethanolamine (N-dod-
PE), were prepared by conjugating different molar ratios of antibodies against VCAM1 (aVCAM1) and 
E-selectin (aE-selectin). Increased binding was observed when immunoliposomes complemented the 
presentation of VCAM1:E-selectin expressed on TNF-α activated ECs. The 1:1 aVCAM1:aE-selectin 
liposomes had maximal binding at both 6 and 24 h on IL-1α activated ECs due to differences in 
molecular organization. The results demonstrate that liposomes targeting to inflamed endothelium 
may be optimized by exploiting the dynamic expression of VCAM1 and E-selectin on the EC surface. 
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Abstract 
Inflammation is in part defined by the transient upregulation of cell adhesion molecules 
on the surface of endothelial cells (ECs) in response to cytokines. We hypothesized that 
liposomes with a complementary surface presentation of antibodies to the pattern of 
molecules on the EC surface may enhance targeting. We quantified the expression of 
vascular cell adhesion molecule-1 (VCAM1) and endothelial leukocyte cell adhesion 
molecule-1 (E-selectin) on ECs upon exposure to either tumor necrosis factor-α (TNF-α) 
or interleukin-1α (IL-1α) as a function of time. Liposomes, composed of 95 mol% 
dioleoyl phosphatidylcholine (DOPC) and 5 mol% dodecanyl phosphatidylethanolamine 
(N-dod-PE), were prepared by conjugating different molar ratios of antibodies against 
VCAM1 (aVCAM1) and E-selectin (aE-selectin). Increased binding was observed when 
immunoliposomes complemented the presentation of VCAM1:E-selectin expressed on 
TNF-α activated ECs. The 1:1 aVCAM1:aE-selectin liposomes had maximal binding at 
both 6 and 24 h on IL-1α activated ECs due to differences in molecular organization. The 
results demonstrate that liposomes targeting to inflamed endothelium may be optimized 
by exploiting the dynamic expression of VCAM1 and E-selectin on the EC surface. 
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1. Introduction 
 
The transient expression of cell adhesion molecules on endothelial cells (ECs) presents a 
targeting opportunity for inflamed endothelium [1-3]. Intercellular cell adhesion molecule-1 
(ICAM1), endothelial leukocyte adhesion molecule-1 (E-selectin), and vascular cell adhesion 
molecule-1 (VCAM1) are upregulated on ECs upon activation with inflammatory cytokines [4-
6]. Each of these molecules has been investigated for targeting [7-9]; however, no binding 
studies have correlated the ratio of antibodies on drug delivery vehicles with the presentation of 
target molecules on ECs.  
Targeting multiple, transiently-upregulated cell adhesion molecules on ECs may amplify 
binding specificity and cellular uptake of drug delivery vehicles. Microbubble contrast agents 
conjugated with dual targeting antibodies against VCAM1 and P-selectin bound almost twice as 
effectively as single-targeting microbubbles [10]. Similarly, the adhesion of microspheres 
bearing antibodies against ICAM1 (aICAM1) and sialyl Lewis
x
, a selectin ligand, was dependent 
on the concentration of both ligands [11, 12]. Our previous reports also demonstrated that the 
antibody ratio (aICAM1:aE-selectin) and lipid mobility influenced cellular binding [13].  
These observations, however, did not account for the fact that the cell surface is 
spatiotemporally dynamic. Cell adhesion molecules, such as E-selectin and ICAM1, have been 
reported to cluster following their engagement in a cytokine or shear-induced response [14]. 
Clustering of ICAM1 and E-selectin in lipid raft microdomains is required for subsequent cell 
signaling and gene expression [15, 16]. Binding of liposomes, targeted to ICAM1 and E-selectin, 
was reduced to the non-specific level when lipid raft formation was inhibited by addition of a 
cholesterol chelation agent, methyl-β-cyclodextrin. [17]. These reports clearly demonstrate the 
importance of molecular organization on the EC surface in liposome targeting. 
*Manuscript
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In addition to clustering, the expression of cell adhesion molecules on ECs changes 
temporally after exposure to cytokines. Several studies have reported the time-course expression 
of cell adhesion molecules in response to different inflammatory cytokines. Scholz et al. showed 
that interleukin-1β (IL-1-induced VCAM1 and E-selectin expression regressed after 8 h while 
ICAM1 was maintained for 72 h [18]. With IL-1, E-selectin expression peaked at 6 h whereas 
platelet endothelial cell adhesion molecule-1 (PECAM1) reached a plateau after 12 h [19]. The 
expression trend for each cell adhesion molecule corresponds to the inflammatory response, 
where they mediate neutrophil rolling, adhesion, arrest and transmigration [20].  
 Changes in the endothelial phenotype may be important in the design of drug delivery 
vehicles that target the endothelium. Targeting of drug delivery vehicles to inflamed ECs may be 
tailored to the latent stage of the immune response, resulting in consistent delivery of therapeutic 
agents at the target site (Figure 1).  
In this report, we characterized the expression of VCAM1 and E-selectin as a function of 
time in response to IL-1 and TNF-. Liposomes were modified with different molar ratios of 
aVCAM1:aE-selectin to evaluate optimum binding to activated ECs as a function of time. Drug 
delivery vehicles designed to target inflamed endothelium may benefit from understanding the 
temporal dynamics of molecules expressed on the EC surface. 
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2. Experimental Methods 
 
Materials 
 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-dodecanyl (N-dod-PE) and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) were purchased from Avanti Polar Lipids 
(Alabaster, AL). Human recombinant interleukin-1 (IL-1), mouse anti-human VCAM1 
(aVCAM1), mouse anti-human E-selectin (aE-selectin) monoclonal antibodies (mAbs), and IgG1 
isotype (mAb) were purchased from R&D Systems (Minneapolis, MN). N-ethyl-N’-(3-
dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), bovine serum 
albumin (BSA), human recombinant tumor necrosis factor- (TNF-), rhodamine-B isothio-
cyanate-conjugated dextran (10 kDa MW), ammonium molybdate, ascorbic acid, anhydrous 
dimethyl sulfoxide (DMSO), and ethanol (EtOH) were purchased from Sigma (St. Louis, MO). 
Formaldehyde was obtained from EMD Chemicals, Inc. (Gibbstown, NJ). Fluorescein 
isothiocyanate (FITC)-conjugated goat anti-mouse (FITC)-conjugated mouse anti-rat, 
tetramethyl rhodamine isothio-cyanate (TRITC)-conjugated rabbit anti-sheep secondary 
antibodies were obtained from Abcam (Cambridge, MA). Sheep aE-selectin polyclonal 
antibodies were purchased from Leinco Technologies (St. Louis, MO). Dulbecco’s phosphate 
buffered saline (PBS), 0.25% trypsin/2.6 mM EDTA, and Hoechst 33258 were obtained from 
Invitrogen (Carlsbad, CA).  
 
Liposome preparation 
Unilamellar liposomes were prepared by the extrusion method as previously described 
[13]. A mixture of DOPC:N-dod-PE (95:5 mol%) in chloroform was dried in a rotary evaporator 
under reduced pressure. The lipids were then dissolved in a mixture of DMSO:EtOH (7:3 v/v). 
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Lipid mixtures (0.3 mL) were injected in 3 mL PBS (pH 7.4) with or without rhodamine-
conjugated dextran (1 mg/mL) while being agitated at 650 rpm with a stir bar to yield 50 mM 
lipid. The multilamellar vesicles were subjected to 10 freeze-thaw cycles (utilizing liquid 
nitrogen) prior to extrusion. Large unilamellar vesicles were prepared by utilizing a LIPEX
TM
 
extruder (Northern Lipids, Burnaby, Canada). Vesicles were extruded 10 times through a 200 nm 
polycarbonate membrane (Whatman Nucleopore 25 mm track-etched membranes, GE 
Healthcare Biosciences, Piscataway, NJ). Dextran-encapsulated liposomes were dialyzed against 
PBS using a Slide-A-Lyzer dialysis cassette (MWCO 20 kDa, Pierce Biotechnology, Inc., 
Rockford, IL) overnight at room temperature (RT). Liposome size was measured by dynamic 
light scattering on a ZetaPALS analyzer (Brookhaven Instruments, Corp., Holtsville, NY) in PBS 
(pH 7.4).  
The concentration of lipid in solution was determined by a phosphate assay as previously 
described [13]. Briefly, a diluted liposome sample was ashed with 0.2 mL sulfuric acid (10% 
v/v) at 200°C for 1 h, followed by addition of 50 l hydrogen peroxide (30% v/v) and further 
heating at 200°C for 40 min. After the sample was cooled down to RT, 480 mL deionized water 
and 0.5 mL of color reagent (0.5% w/v ammonium molybdate, 2 % w/v ascorbic acid) were 
added to each sample followed by heating at 45°C for 20 min. The samples were read at 820 nm 
using a Spectramax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). A 
calibration curve was prepared with known phosphate quantities.  
 
Preparation of antibody-labeled liposomes and microspheres 
Mouse aVCAM1 and mouse aE-selectin mAbs were conjugated to liposomes via the N-
dod-PE anchor. EDC (2 mg) and NHS (3 mg) were added to 1 mol lipid (liposomes) in PBS 
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(pH 7.4) and incubated for 6 h at RT. Excess EDC and NHS were removed using the Zeba Spin 
desalting column (MWCO 7 kDa, Pierce Biotechnology, Inc.). IgG1 isotype (100 mol%, 
unspecific liposome) or mixtures of aVCAM1:aE-selectin (1:0, 1:1, 1:4, 1:8, 1:20, and 0:1 molar 
ratios) were added to EDC-modified liposomes at a molar ratio of 1:1000 antibody:phospholipids 
and incubated overnight at RT. Free antibodies were separated using a Sepharose CL-4B column 
(Fractionation range: 60-20,000 kDa, Sigma).  
 To determine the antibody density of aVCAM1 and aE-selectin on liposomes, 2-micron 
borosilicate beads (Duke Scientific, Palo Alto, CA), large enough to be detected by flow 
cytometry, were coated with a lipid bilayer. Microbeads and PC:N-dod-PE (95:5) liposomes 
were agitated in PBS for 6 h. Microbeads coated with PC:N-dod-PE bilayers were washed 3 
times with PBS through centrifugation-suspension cycles to separate free liposomes. In order to 
simultaneously label both aVCAM1 and aE-selectin, sheep aE-selectin antibodies were 
conjugated on microbeads instead of mouse aE-selectin antibodies. Conjugation of different 
ratios of aVCAM1:aE-selectin and control IgG (nonspecific binding) to microbeads was 
performed as described above using EDC/NHS chemistry. After free primary antibodies were 
separated, microbeads were conjugated with FITC-conjugated goat anti-mouse (aVCAM1 
binding) and TRITC-conjugated rabbit anti-sheep (aE-selectin binding) secondary antibodies (10 
l, 10 ng/mL) overnight at 4°C. The secondary antibodies were separated using suspension-spin 
cycles. The density of aE-selectin and aVCAM1 conjugated to microbeads was determined with 
reference to Quantum™ Simply Cellular® anti-mouse IgG microbeads (Bangs Laboratory, Inc., 
Fishers, IN), which have defined numbers of antibody binding sites per bead.  The microbeads 
were stained with FITC-conjugated mouse anti-rat secondary antibodies using the protocol  
provided by the manufacturer.  
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Cell culture 
Human umbilical vein endothelial cells (ECs) were grown in endothelial growth medium-
2 (EGM-2) with supplements as described by the distributor (Lonza, Allendale, NJ). Cells were 
maintained at 37°C in a humidified incubator with 5% CO2 and used for experiments at passages 
2-5. Growth medium was changed the day after cell seeding and every other day thereafter.  
 
VCAM1 and E-selectin immunostaining 
ECs (2x10
5
 cells) were seeded on 18x18 mm
2
 coverslips in 6-well plates with 2 mL 
media (VWR, West Chester, PA) and cultured overnight at 37°C. Cells were incubated with IL-
1 at 5 ng/mL or TNF- at 20 ng/mL in fresh EGM-2 media the next day for 6 h or 24 h. After 
medium was removed, cells were rinsed with PBS three times and fixed with 4% formaldehyde 
in PBS at RT for 15 min followed by washing with PBS. Samples were blocked with 1% BSA in 
PBS (1% BSA) at 4°C for 1 h. Samples were then stained with aVCAM1 and aE-selectin mAbs 
(10 ng/mL in 1% BSA) at 4°C for 2 h and rinsed with PBS. Samples were incubated with FITC-
conjugated goat anti mouse (1:300), TRITC-conjugated rabbit anti-sheep secondary mAbs 
(1:300) and Hoescht 33258 (1:1000) at 4°C for 1 h followed by washing with PBS. Samples 
were then mounted on microscope slides (3”x1”, VWR) with VECTASHIELD® mounting 
medium (Vector Laboratories, Burlingame, CA), and sealed. Samples were examined under an 
Axiovert 200 inverted fluorescent microscope (Carl Zeiss, Thornwood, NY) equipped with a 
Hammamatsu CCD camera (Bridgewater, NJ). Digital images were captured with AxioVision 
digital image processing software (Zeiss). 
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VCAM1 and E-selectin expression  
VCAM1 and E-selectin expression by ECs was evaluated by flow cytometry after 1, 6, 
12, and 24 h incubations with either IL-1 (5 ng/mL) or TNF- (20 ng/mL). Quantification of 
the density of molecules on the surface was determined using Quantum™ Simply Cellular® 
microbeads. After ECs were activated with IL-1 or TNF-, 106 cells were collected from a 6-
well plate, spun down, and resuspended with ice cold 1% BSA in PBS. ECs were rinsed 3 times 
through suspension-spin cycles and blocked with 1% BSA in PBS for 30 min in an ice bath. ECs 
were incubated with mouse anti-human VCAM1 and sheep anti-human E-selectin mAbs (1 mL, 
10 ng/mL) for 30 min in an ice bath. After rinsing with 1% BSA in PBS 3 times to remove free 
mAbs, ECs were stained with FITC-conjugated goat anti-mouse and TRITC-conjugated rabbit 
anti-sheep secondary antibodies for 30 min in an ice bath. ECs were finally rinsed with 1% BSA 
in PBS 3 times, resuspended in PBS, and analyzed by flow cytometry.  
 
Liposome uptake by ECs 
Liposome binding by ECs was analyzed using flow cytometry as previously described 
[21, 22]. ECs were seeded in 6-well plates (3x10
5 
cells/well) and allowed to adhere overnight. 
After activation with IL-1 or TNF- for 6 h or 24 h, ECs were incubated overnight at 37°C 
with: (1) dextran-loaded nonspecific (IgG1) liposomes; and (2) dextran-loaded liposomes 
conjugated with different ratios of aVCAM1:aE-selectin mAbs. The concentration used was 1 
μmol lipid/106 cells.  
Treated ECs were washed with PBS, harvested using trypsin/EDTA solution, and 
collected in a polystyrene culture tube. Cells were washed with PBS three times. Liposomes 
were not detected by fluorescence in the trypsin solution used to remove ECs [17]. Binding data 
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were acquired using an LSRII flow cytometry (BD Immunocytometry Systems, San Jose, CA) 
and analyzed with WEASEL software developed by WEHI (Parkville, Australia). The fold-over 
isotype value was calculated by dividing the mean fluorescence intensity for liposomes 
conjugated with aVCAM:aE-selectin by that of the isotype-conjugated liposomes. Significant 
differences in liposome uptake were evaluated using a 2-way ANOVA analysis. A P value less 
than 0.05 was considered statistically significant.  
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3. Results and Discussion 
 
Characterization of liposomes  
Liposomes were prepared from 95 mol% DOPC and 5 mol% N-dod-PE . The diameters 
of unconjugated DOPC:N-dod-PE liposomes were 205 ± 5 nm, as determined from dynamic 
light scattering. After conjugation with aVCAM1 and aE-selectin, liposome diameters increased 
to 223 ± 3 nm; the diameters were similar for all liposome formulations. The antibody density 
and aVCAM1:aE-selectin ratio were determined using standardized microbeads (Table 1). The 
average antibody density for 1:0 aVCAM:aE-selectin ratio was 6703 ± 379 molecules/m2 or 
842 ± 47 molecules/liposome; this is comparable to other reports (7000 molecules/m2 [32], 
4100 molecules/m2 [33]).  
 
VCAM1 and E-selectin changes temporally 
Inflammatory cytokines were used to upregulate the expression of VCAM1 and E-
selectin on ECs as observed by immunostaining at 6 and 24 h (Figure 2). The surface expression 
of VCAM1 and E-selectin on TNF- and IL-1-activated ECs was quantified as a function of 
time (Figure 3). The expression of VCAM1 and E-selectin was affected by the duration of 
exposure, but not cytokine type (no statistical difference, p > 0.05). The density of E-selectin 
peaked at 6 h by ten-fold and nine-fold relative to unactivated ECs for both TNF- and IL-1 
respectively. VCAM1 increased by three- and two-fold relative to expression on unactivated ECs 
after 24 h of exposure to TNF- and IL-1, respectively. The surface expression of VCAM1 and 
E-selectin on activated ECs was used to define a complementary antibody surface presentation 
on liposomes.  
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Complementary liposomes increase cellular binding 
 Liposomes with different ratios of aVCAM1:aE-selectin were incubated with cytokine-
activated ECs to observe the sensitivity of EC surface expression to liposome antibody 
presentation. ECs are known to transiently express VCAM1 and E-selectin in response to 
cytokines; this reproducible gene expression profile makes ECs a good model system for 
studying how changes in the EC surface presentation affects liposome targeting [23]. EC surface 
expression of VCAM1 and E-selectin was similar for IL-1 and TNF-, approximately 1:20 and 
1:1 VCAM1:E-selectin at 6 and 24 h, respectively (Figure 3). EC binding of dextran-
encapsulating liposomes was evaluated by flow cytometry as a function of the aVCAM1:aE-
selection ratio (1:0, 1:1, 1:4, 1:8, and 0:1) and activation time (6 and 24 h) (Figure 4A and 4B).  
At early times, E-selectin is highly expressed in activated ECs; thus, liposomes 
presenting more aE-selectin exhibit greater binding. Liposome binding increased from 1.7-fold 
to 3.7-fold relative to IgG presenting liposomes, when the aVCAM1:aE-selectin ratio was 
reduced from 1:0 to 1:8 on TNF-α activated ECs, respectively. At later times, the increase in 
VCAM1 density on TNF-α activated ECs resulted in greater binding of liposomes with a 
comparable presentation of aVCAM1:aE-selectin. Liposome binding at 24 h peaked at 1:1 
aVCAM1:aE-selectin; this was 2.3-fold greater than 1:0 and 0:1 aVCAM1:aE-selectin liposome 
formulations and ~4-fold greater than the IgG conjugated liposome control. Cellular binding at 
all non-optimal ratios were significantly lower than the 1:1 aVCAM1:aE-selectin liposomes (p < 
0.001). 
For TNF-α, maximal binding was achieved when liposomes complemented the 
expression of VCAM1 and E-selectin on the EC surface; peak binding was observed at 1:8 and 
1:1 aVCAM1:aE-selectin at 6 and 24 h, respectively (Figure 4). This was analogous to the ratio 
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of VCAM1:E-selectin expressed on the EC surface (Figure 3). No significant difference in 
binding was observed between the 1:20 and 0:1 aVCAM1:aE-selectin liposome formulation 
except for ECs activated for 24 h with TNF-α (p < 0.05) (Supplementary Figure 1A and 1B). 
Complementary liposomes had significantly higher binding than the 1:0 and 0:1 aVCAM1:aE-
selectin liposomes, confirming a cooperative interaction between colocalized VCAM1 and E-
selectin [17].  
Both TNF-α and IL-1α activated ECs exhibited a ~4-fold increase in binding at 6 h for 
the 1:8 aVCAM1:aE-selectin liposomes. However, the 1:1 aVCAM1:aE-selectin liposomes 
exhibited maximal binding on IL-1α activated ECs at both 6 and 24 h. The inconsistency in 
binding may be a result of the organization of the VCAM1 and E-selectin on the surface. At 6 h, 
E-selectin is observed predominantly in the perinuclear region in IL-1α activated ECs, which 
does not consistently overlap with VCAM1 (Figure 2A).  Although the average ratios of 
VCAM1:E-selectin are similar between TNF-α and IL-1α, the organization of the molecules may 
differ upon assembly within lipid rafts. We have previously reported that the organization of cell 
adhesion molecules within lipid rafts is critical for achieving cooperative binding of liposomes to 
activated ECs [17].  
EC surface expression is used to regulate leukocyte-EC interactions [2, 26]. E-selectin, 
whose expression is restricted on activated ECs, mediates the homing and rolling of leukocytes 
during the inflammatory response [27]. VCAM1 is virtually absent on normal endothelium; its 
expression is more widely expressed by cytokine-activated endothelial cells [34, 35. Recently, 
VCAM1 expression has been shown to cluster primarily on the apical surface of ECs [23, 31]. 
The upregulation of VCAM1 and E-selectin is not enough to target inflamed ECs. The 
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organization of the cell adhesion molecules is important in regulating liposome binding and cell-
cell interactions.  
Our results suggest that liposomes, designed to be complementary to the activated EC 
surface at a particular time, may be optimized to deliver agents at specific stages of 
inflammation. Liposome binding is dependent on the density and organization expressed of 
molecules on ECs, which is regulated by the exposure time and type of cytokine.  
In this report, we have demonstrated that liposomes with a complementary surface 
presentation to ECs resulted in increased binding relative to liposomes presenting either 
aVCAM1 or aE-selectin alone. Transiently-upregulated cell adhesion molecules may be 
exploited to design drug delivery vehicles that will have sustained binding to activated ECs. 
 
5. Conclusions 
Liposomes were targeted to IL-1 and TNF- activated ECs via cell adhesion molecules, 
VCAM1 and E-selectin, expressed transiently after cytokine stimulation. Maximal binding was 
achieved for TNF-α activated ECs when the ratio of aVCAM1:aE-selectin on the liposome 
surface was complementary to the VCAM1:E-selectin expression. However, the 1:1 
aVCAM1:aE-selectin liposomes had maximal binding on ECs activated with IL-1α at both 6 and 
24 h. The density and organization of cell adhesion molecules on activated ECs is important for 
cooperative binding. Efficient targeting may be achieved by understanding the transient 
expression, relative density, and organization of target EC surface molecules. 
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FIGURE CAPTIONS 
 
Figure 1.  Schematic of immunoliposomal drug delivery vehicles targeting the transient expression of VCAM1 and E-
selectin on ECs.  VCAM1 and E-selectin are transiently expressed on ECs after activation with inflammatory 
cytokines TNF-α and IL-1α.  E-selectin expression is instantaneous while VCAM1 is progressively expressed with 
time.  Optimum binding of immunoliposomes can be continuously enhanced by complimenting the antibody surface 
presentation of aVCAM1 and aE-selectin to the VCAM1 and E-selectin expression on ECs over time (Δt).   
 
Figure 2.  VCAM1, E-selectin, and IgG1 isotype control immunostaining for TNF-α and IL-1α-stimulated and 
unstimulated ECs.  ECs were activated with TNF-α and IL-1α for 6 h (A) and 24 h (B), then fixed, and immunostained 
with aVCAM1 and aE-selectin.  After activation with either TNF-α or IL-1α, ECs transiently expressed VCAM1 and E-
selectin.  Scale bar, 10 μm.     
 
Figure 3.  Time-course expression of VCAM1 and E-selectin on TNF-α and IL-1α activated ECs.   ECs were 
activated with either TNF-α or IL-1α for various durations.  Expression of VCAM1 (A) and E-selectin (B) was 
determined using flow cytometry as a function of time.  VCAM1 expression increased with time for up to 24 h while E-
selection peaked at 6 h for both TNF-α and IL-1α.    
 
Figure 4.  Uptake of immunoliposomes conjugated with various ratios of aVCAM1 and aE-selectin by ECs.  ECs 
activated with TNF-α and IL-1α were treated with rhodamine-labeled dextran encapsulated in DOPC:N-dod-PE (95:5 
mol:mol) for either 6 h (A) or 24 h (B).  Flow cytometry was used to determine the cellular uptake of DOPC 
immunoliposomes conjugated with various ratios of aVCAM1:aE-selectin.  Results are presented relative to uptake by 
IgG1-labeled liposomes (In (A) statistical significance was observed between TNF-α 1:4 and 1:8 aVCAM1:aE-selectin 
groups vs. all other TNF-α conditions and between IL1-α 1:1 aVCAM1:aE-selectin vs. all other IL1-α conditions.    In 
(B) statistical significance was observed between TNF-α 1:1 aVCAM1:aE-selectin group vs. all other TNF-α 
conditions and between IL1-α 1:1 aVCAM1:aE-selectin vs. all other IL1-α conditions. *** p < 0.001 as measured by 2-
way ANOVA).  
 
Supplementary Figure 1.  Uptake of immunoliposomes conjugated with 1:20 and 0:1 ratios of aVCAM1 and aE-
selectin by ECs.  ECs activated with TNF-α and IL-1α for either 6 h (A) or 24 h (B) were treated with rhodamine-
labeled dextran encapsulated in DOPC:N-dod-PE (95:5 mol:mol) .  Results are presented relative to uptake by IgG1-
labeled liposomes (* p < 0.05). 
 
 
 
Captions
Table 1.  Antibody density and zeta potential of 95:5 DOPC:N-dod-PE immunoliposomes.  All 
liposomes were assumed to have a surface area of 0.126 µm
2
. 
 
 
Ratio 
aVCAM1:aE-selectin 
 
aVCAM1   
(molecules/liposome) 
 
 
aE-selectin 
(molecules/liposome) 
 
 
Zeta potential (mV) 
 
1:0 
 
842 ± 47 
 
- 
 
1.1 ± 0.6 
1:1 571 ± 30 488 ± 41 -0.1 ± 2.3 
1:4 215 ± 19 621 ± 64 0.9 ± 0.6 
1:8 91 ± 7 623 ± 54 1.3 ± 0.7 
0:1 - 849 ± 89 0.5 ± 3.3 
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